Table 2 Characteristics of DESIR patients satisfying selected criteria sets
|  | Canada n = 169 | France n = 197 | UK n = 86 | Germany n = 175 | Hong Kong n = 61 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Anti-TNF non-user (n = 98) | Anti-TNF user (n = 71) | Anti-TNF non-user (n = 117) | Anti-TNF user (n = 80) | Anti-TNF non-user (n = 46) | Anti-TNF user (n = 40) | Anti-TNF non-user (n = 108) | Anti-TNF user (n = 67) | Anti-TNF non-user (n = 29) | Anti-TNF user (n = 32) | |
At baseline | ||||||||||
 Age | 32.8 ± 8.5 | 33.5 ± 9.3 | 33.2 ± 8.7 | 33 ± 9.1 | 33 ± 7.6 | 32.6 ± 9.6 | 32.7 ± 7.9 | 33.1 ± 9.4 | 35 ± 8 | 31.8 ± 8.5 |
 Male | 53 (54.1%) | 40 (56.3%) | 58 (49.6%) | 59 (53.8%) | 27 (58.7%) | 24 (60%) | 59 (54.6%) | 37 (55.2%) | 17 (58.6%) | 19 (59.4%) |
 Post-secondary education | 55 (56.1%) | 42 (59.2%) | 65 (55.6%) | 48 (60%) | 22 (47.8%) | 20 (50%) | 60 (55.6%) | 35 (59.7%) | 11 (37.9%) | 14 (43.8%) |
 Married | 58 (59.2%) | 40 (59.2%) | 71 (60.7%) | 48 (60%) | 24 (52.2%) | 23 (57.5%) | 69 (63.9%) | 40 (59.7%) | 17 (58.6%) | 19 (59.4%) |
 Smoking | 41 (41.8%) | 36 (50.7%) | 50 (42.7%) | 38 (47.5%) | 23 (50.0%) | 22 (55.0%) | 44 (40.7%) | 35 (52.2%) | 12 (41.4%) | 19 (59.4%) |
 Disease duration | 1.5 ± 0.9 | 1.6 ± 0.8 | 1.6 ± 0.9 | 1.6 ± 0.8 | 1.7 ± 0.9 | 1.6 ± 0.8 | 1.5 ± 0.9 | 1.6 ± 0.8 | 1.7 ± 0.9 | 1.6 ± 0.8 |
 Peripheral Arthritis | 54 (55.1%) | 49 (69%) | 65 (55.6%) | 55 (68.8%) | 22 (47.8%) | 25 (62.5%) | 56 (51.9%) | 46 (68.7%) | 13 (44.8%) | 21 (65.6%) |
 HLA-B27: positive | 59 (60.2%) | 44 (62%) | 66 (56.4%) | 48 (60%) | 32 (69.6%) | 25 (62.5%) | 83 (76.9%) | 46 (68.7%) | 18 (62.1%) | 19 (59.4%) |
 Radiographic sacroiliitis | 42 (42.9%) | 40 (56.3%) | 49 (41.9%) | 44 (55.0%) | 28 (60.9%) | 30 (75.0%) | 49 (45.4%) | 41 (61.2%) | 15 (51.7%) | 25 (78.1%) |
 Sacroiilitis or spine inflammation on MRI | 67 (68.4%) | 49 (69.0%) | 67 (57.3%) | 49 (61.3%) | 25 (54.3%) | 26 (65.0%) | 80 (74.1%) | 52 (77.6%) | 12 (41.4%) | 21 (65.6%) |
 BASDAI ≥ 4 | 74 (75.5%) | 67 (94.4%) | 91 (77.8%) | 76 (95.0%) | 34 (73.9%) | 39 (97.5%) | 78 (72.2%) | 62 (92.5%) | 21 (72.4%) | 31 (96.9%) |
 CRP > 10 mg/L | 24 (24.5%) | 31 (43.7%) | 25 (21.4%) | 33 (41.3%) | 8 (17.4%) | 21 (52.5%) | 26 (24.1%) | 32 (47.8%) | 5 (17.2%) | 14 (43.8%) |
 Physician’s global assessment ≥4 | 76 (77.6%) | 66 (93.0%) | 92 (78.6%) | 75 (93.8%) | 33 (71.7%) | 38 (95.0%) | 73 (67.6%) | 61 (91.0%) | 20 (69.0%) | 31 (96.9%) |
 Inflammatory back pain ≥ 4 | 79 (80.6%) | 68 (95.8%) | 96 (82.1%) | 76 (95.0%) | 40 (87.0%) | 40 (100%) | 88 (81.5%) | 64 (95.5%) | 25 (86.2%) | 32 (100%) |
 Morning stiffness ≥45 min | 53 (54.1%) | 47 (66.2%) | 62 (53.0%) | 56 (70.0%) | 20 (43.5%) | 31 (77.5%) | 57 (52.8%) | 47 (70.1%) | 18 (62.1%) | 30 (93.8%) |
 Patient global assessment ≥4 | 73 (74.5%) | 65 (91.5%) | 88 (75.2%) | 74 (92.5%) | 33 (71.7%) | 38 (95.0%) | 79 (73.1%) | 60 (89.6%) | 23 (79.3%) | 31 (96.9%) |
At criteria satisfaction | ||||||||||
 BASDAI | 56.2 ± 12.7 | 60.6 ± 11.4 | 55.4 ± 12.2 | 60.9 ± 10.9 | 52.8 ± 10.5 | 58.9 ± 11.9 | 55.5 ± 12.7 | 58.7 ± 10.8 | 56.1 ± 12 | 59.3 ± 11.7 |
 BASFI | 35.8 ± 21.8 | 43.9 ± 20.2 | 35.9 ± 21.5 | 45 ± 19.8 | 30.8 ± 20 | 47.4 ± 20.8 | 36.5 ± 23.5 | 42.1 ± 19.7 | 39 ± 21.6 | 46.5 ± 22 |
 SF-36 | 0.6 ± 0.1 | 0.5 ± 0.1 | 0.6 ± 0.1 | 0.5 ± 0.1 | 0.6 ± 0.1 | 0.5 ± 0.1 | 0.6 ± 0.1 | 0.5 ± 0.1 | 0.6 ± 0.1 | 0.5 ± 0.1 |
 Physician’s global assessment | 5.3 ± 1.2 | 6.7 ± 1.6 | 5.3 ± 1.2 | 6.8 ± 1.5 | 4.7 ± 1.7 | 6.8 ± 1.7 | 4.5 ± 1.8 | 6.4 ± 2 | 5 ± 1.6 | 6.7 ± 1.6 |
 CRP | 10.9 ± 18.6 | 20.1 ± 24.6 | 9.5 ± 17.2 | 18.8 ± 23.8 | 7.7 ± 9.3 | 22.3 ± 25.5 | 10.9 ± 12.5 | 19.7 ± 23.7 | 7.6 ± 10.2 | 15.8 ± 20.6 |